MA54825A - Modulateurs de gpr35 - Google Patents

Modulateurs de gpr35

Info

Publication number
MA54825A
MA54825A MA054825A MA54825A MA54825A MA 54825 A MA54825 A MA 54825A MA 054825 A MA054825 A MA 054825A MA 54825 A MA54825 A MA 54825A MA 54825 A MA54825 A MA 54825A
Authority
MA
Morocco
Prior art keywords
gpr35
modulators
gpr35 modulators
Prior art date
Application number
MA054825A
Other languages
English (en)
Inventor
Robert Higuchi
Original Assignee
Prometheus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometheus Biosciences Inc filed Critical Prometheus Biosciences Inc
Publication of MA54825A publication Critical patent/MA54825A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA054825A 2019-01-24 2020-01-23 Modulateurs de gpr35 MA54825A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962796459P 2019-01-24 2019-01-24
US201962873703P 2019-07-12 2019-07-12
US201962928223P 2019-10-30 2019-10-30

Publications (1)

Publication Number Publication Date
MA54825A true MA54825A (fr) 2021-12-01

Family

ID=71733100

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054825A MA54825A (fr) 2019-01-24 2020-01-23 Modulateurs de gpr35

Country Status (13)

Country Link
US (2) US11053251B2 (fr)
EP (1) EP3914256B1 (fr)
JP (1) JP7588077B2 (fr)
KR (1) KR102863894B1 (fr)
CN (1) CN113631168B (fr)
AU (1) AU2020210930B2 (fr)
BR (1) BR112021014566A2 (fr)
CA (1) CA3127786A1 (fr)
IL (1) IL285074B2 (fr)
MA (1) MA54825A (fr)
MX (1) MX2021008941A (fr)
TW (1) TWI845600B (fr)
WO (1) WO2020154492A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
WO2020232125A1 (fr) 2019-05-14 2020-11-19 Prometheus Biosciences, Inc. Méthodes, systèmes et dispositifs de sélection de patient tl1a
CA3186635A1 (fr) * 2020-07-23 2022-01-27 Robert Higuchi Agents therapeutiques ciblant gpr35
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
GB202303387D0 (en) * 2023-03-08 2023-04-19 Thirtyfivebio Ltd Compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005119252A2 (fr) * 2004-05-26 2005-12-15 Arena Pharmaceuticals, Inc. Gpr35 et modulateur de gpr35 utilises pour traiter des troubles metaboliques
GB1421970A (en) * 1973-06-12 1976-01-21 May & Baker Ltd 8-azapurin-6-one derivatives
GB1338235A (en) 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
US4052390A (en) * 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
GB1561345A (en) 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4923874A (en) 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
FR2845993B1 (fr) * 2002-10-16 2005-02-11 Univ Pasteur Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques
WO2005085867A2 (fr) * 2004-02-27 2005-09-15 Pfizer Japan, Inc. Recepteur gpr35
US20070287630A1 (en) 2006-06-12 2007-12-13 Driwater, Inc. Moisturizing agent with nutrients
WO2012167053A1 (fr) 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Nouveaux modulateurs du système immunitaire
EP4610368B1 (fr) 2013-08-05 2026-02-04 Twist Bioscience Corporation Banques de gènes synthétisés de novo
US20150273088A1 (en) * 2014-03-28 2015-10-01 Washington University Zaprinast analogues as glutaminase inhibitors and methods to predict response thereto
KR102658324B1 (ko) 2014-06-29 2024-04-18 프로파일 프러덕츠 엘엘씨 나무껍질 및 목재 섬유 성장 배지
WO2018195328A1 (fr) * 2017-04-20 2018-10-25 Cedars-Sinai Medical Center Procédés de prédiction de non-réponse à un traitement anti-tnf chez des sujets atteints d'une affection intestinale inflammatoire
TW202014217A (zh) * 2018-04-27 2020-04-16 美國錫安山醫學中心 標靶gpr35以治療發炎性腸病症的組合物及方法
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
CA3128942A1 (fr) 2019-02-08 2020-08-13 Cedars-Sinai Medical Center Procedes, systemes et kits pour traiter une maladie inflammatoire ciblant skap2
MA54903A (fr) 2019-02-08 2021-12-15 Cedars Sinai Medical Center Méthodes, compositions et kits pour traiter une maladie inflammatoire ciblant il18r1
WO2020232125A1 (fr) 2019-05-14 2020-11-19 Prometheus Biosciences, Inc. Méthodes, systèmes et dispositifs de sélection de patient tl1a
WO2021108694A1 (fr) 2019-11-27 2021-06-03 Cedars-Sinai Medical Center Prédiction de manifestations extra-intestinales de maladies intestinales inflammatoires
CA3186635A1 (fr) 2020-07-23 2022-01-27 Robert Higuchi Agents therapeutiques ciblant gpr35
BR112023009172A2 (pt) 2020-11-13 2023-10-03 Cedars Sinai Medical Center Métodos, sistemas e kits para tratamento de doenças inflamatórias direcionados à tl1a
EP4263585A4 (fr) 2020-12-21 2024-11-27 Cedars-Sinai Medical Center Compositions thérapeutiques de tl1a et méthodes de traitement les utilisant

Also Published As

Publication number Publication date
IL285074B1 (en) 2024-08-01
CN113631168A (zh) 2021-11-09
EP3914256A1 (fr) 2021-12-01
CN113631168B (zh) 2024-11-19
TWI845600B (zh) 2024-06-21
JP2022518523A (ja) 2022-03-15
BR112021014566A2 (pt) 2022-01-04
US20200239476A1 (en) 2020-07-30
IL285074A (en) 2021-09-30
TW202043234A (zh) 2020-12-01
US11053251B2 (en) 2021-07-06
WO2020154492A1 (fr) 2020-07-30
JP7588077B2 (ja) 2024-11-21
MX2021008941A (es) 2021-10-13
EP3914256B1 (fr) 2024-05-29
US20210380590A1 (en) 2021-12-09
KR102863894B1 (ko) 2025-09-23
IL285074B2 (en) 2024-12-01
AU2020210930A1 (en) 2021-09-09
KR20210119485A (ko) 2021-10-05
EP3914256A4 (fr) 2022-09-28
CA3127786A1 (fr) 2020-07-30
AU2020210930B2 (en) 2025-08-14
US11773101B2 (en) 2023-10-03

Similar Documents

Publication Publication Date Title
DK3743406T3 (da) Tmem16a modulatorer
ZA202007307B (en) Nlrp3 modulators
MA50014A (fr) Modulateurs de k-ras
EP3861130A4 (fr) Modulateurs génétiques modifiés
MA55328A (fr) Modulateurs de ror-gamma
EP3684368A4 (fr) Modulateurs sélectifs de p2x3
IL281812A (en) Monoacylglycerol lipase modulators
HUE062866T2 (hu) TREX-1 modulátorok
MA53943A (fr) Modulateurs de ror-gamma
GB2596231B (en) Modulators
DK3490986T3 (da) Piperidin-cxcr7-receptormodulatorer
EP3675849A4 (fr) Modulateurs de tétrahydrocannabinol
IL285074A (en) Gpr35 modulators
EP3853365A4 (fr) Modulateurs de l'expression de pnpla3
EP3899024A4 (fr) Modulateurs de l'expression de hsd17b13
EP3601569A4 (fr) Modulateurs de l'expression de pcsk9
DK3749669T3 (da) Ahr-modulatorer
MA53722A (fr) Modulateurs de la monoacylglycérol lipase
IL285772A (en) Treatment with p2x3 modulators
MA51645A (fr) Modulateurs de l'expression de dnm2
EP3374386C0 (fr) Modulateurs du récepteur activé par protéase de type 2
EP4192957A4 (fr) Modulateurs de trpml
EP3532062A4 (fr) Modulateurs de ror-gamma
EP4025957C0 (fr) Modulateur électro-optique
EP4035739A4 (fr) Hydrogel